Although salicylates are widely used as antipyretic agents, the mechanism by which they lower body temperature is controversial. It has been suggested that these compounds act at peripheral sites of inflammation, by suppressing release of endogenous pyrogen from leucocytes exposed to an inflammatory stimulus (1), or by suppressing synthesis and release of fever-inducing prostaglandins (2, 3). Alternatively, considerable evidence in both man (4) and rabbits (5, 6) indicates that salicylates act centrally to lower fever by blocking the action of endogenous pyrogen on certain temperature-sensitive hypothalamic neurons. For example, stable fevers induced by infusions of leucocyte (endogenous) pyrogen in humans persisted for 50 min or so after the infusion was discontinued (4). However, when sodium salicylate was injected intravenously during the continuous pyrogen infusion, temperature fell promptly. This rapid antipyretic effect of salicylate is best explained by a central action rather than by altered production or release of pyrogen from the host's leucocytes.
millipore filter, and stored at 40C. For infusion experiments, 100 mg/ml Na salicylate solution was prepared. One-gram amounts were injected intravenously into rabbits to test for possible endotoxin contamination. Human blood leucocytes were prepared by methods described previously (7) . Briefly, heparinized venous blood was drawn from normal volunteers, separated by dextran sedimentation, and the leucocytes suspended in modified Krebs-Ringer phosphate buffer pH 7.4 with 10 units heparin/ml. Incubation flasks contained 5-7.5 ml of 15% autologous serum-KRP buffer with 1 X 107 leucocytes per ml, glucose 150 mg% and penicillin 6000 units. Salicylate 40 mg% was incubated with leucocytes for one hour before addition of bacteria. Heat-killed Staphylococcus albus, prepared as described previously (7) was used at a ratio of 5-40 bacteria per leucocyte. In experiments with endotoxin, a 1:10 dilution in saline of typhoid vaccine (Monovalent Reference Std NRV-LS # 1, Walter Reed, Washington, D.C.) was filtered just before use through a Swinnex millipore filter, and 0.3-0.5 ml/ 3 X 107 leucocytes was used. Salicylate was added to leucocytes 1 hr after the endotoxin. Flasks were incubated with shaking on a Dubnoff incubator at 370C for several hours, and then placed in a stationary incubator at 370C overnight. In initial experiments with bacteria, phagocytosis was confirmed by examination of coverslip smears two hours after addition of staphylococci.
After incubation, flask contents were centrifuged at 2000g for 30 min, an aliquot of the supematant was cultured in thioglycollate broth to confirm sterility, and the remainder was injected at once or stored at 40C. for [1] [2] [3] [4] [5] days. Pyrogen release was determined by assay in rabbits as described previously (8) . AT represents the maximum height of fever above pre-injection baseline temperature, occurring within 75 min after injection. In some experiments, rabbit temperatures were continuously monitored on a Rustrak recorder. In all experiments, the same rabbits received aliquots of supernatants from control and experimental preparations. Results of pyrogen assay of supernatants, reported in Tables 1 and 2 , were tested for significant differences by means of t-test for paired samples, using responses of the same rabbit to a control and experimental supernatant as one pair. Supernatant from leucocytes incubated without salicylate or activators was determined to give an average temperature rise of less than 0.20C. in all instances.
Rabbit endogenous pyrogen (EP) was prepared as follows. One-hundred and twenty ml. heparinized rabbit blood was centrifuged at 600g, the cells were resuspended in 25 ml plasma, and heparinized KRP buffer containing 150 mg% glucose and 6000 units of penicillin was added to a final volume of 150 ml. Heat-killed staphylococci (1.5 X 1010) were added, and the mixture was shaken gently at 370C overnight. After centrifugation at 2000g for 30 min, the supematant containing EP was removed, an aliquot cultured and assayed for pyrogenicity, and the remainder stored at 40C. Na salicylate for intraperitoneal injection was diluted to 20 mg/ml in KRP buffer, and injected slowly through a blunt infusion needle to provide 250 mg/kg, the dose used by others ( 1).
RESULTS
The results of experiments designed to investigate the effect of salicylate on pyrogen release from human blood cells in vitro are shown in Tables 1 and 2 . Pre-incubation of leucocytes with a high concentration of sodium salicylate (40 mg% ) did not alter the subsequent release of pyrogen after stimulation by phagocytosis (Table 2 ). In fact, in the presence of salicylate, this small dose of endotoxin caused somewhat greater release of pyrogen p = <.02).
A more sensitive, quantitative assay for pyrogen was also carried out in several of these experiments by injecting both a standard pyrogenic dose of each supernatant and one half of this dose. Amounts were adjusted so that the average height of fever for one aliquot of supernatant was about 0.60C and was proportionately decreased by injection of half that amount (for example, see Fig. 1 ). It could then be assumed that the dose-response curve was in its most sensitive range.' As shown in Fig. 1, using Average maximum height of fever + SEM in nine rabbits after injection of supernatants from 18-hr incubations of human blood leucocytes with heat-killed staphylococci ( -) or leucocytes pre-incubated for 1 hr with 40 mg% Na salicylate plus heat-killed staphylococci (A-.i). One dose in different exp2riments was derived from 9.5-14.0 x 10 leucocytes (see text for details). Fig. 2 , curves A and B. Five days later, each rabbit received 250 mg/kg sodium salicylate by intraperitoneal infusion. Temperatures were then recorded, and 1 or 2 hr later, each rabbit was injected intravenously with a second 1-ml aliquot of the pyrogenic supernatant. As shown in Fig. 2 , C, this injection produced only half as much fever as did the first (Curve A). To insure that the test solution had not lost its pyrogenicity, a third 1-ml aliquot was injected two days later. Although the stored material was slightly less pyrogenic than the sample tested initially (Fig. 2, Curves D and A) , it clearly produced more fever than the preceding injection which followed salicylate treatment (Fig. 2, C) . Salicylate thus interfered in vivo with the pyrogenic action of pre-formed endogenous pyrogen.
DISCUSSION
The experiments reported in Tables 1 and 2 indicate that incubation of human blood leucocytes in vitro with a high concentration of salicylate does not alter their capacity to release endogenous pyrogen after stimulation by endotoxin or phagocytosis. The experiments by others (1, 11) in which salicylate appeared to suppress leucocyte pyrogen production differed in several respects from ours. First, rabbit blood or exudate cells were used, rather than human blood leucocytes. Differences in the effects of activators and inhibitors on pyrogen production by cells of different species have been noted (8, 12) , and both metabolic (13, 14) and pyrogen-releasing (15, 16) properties of exudate and blood cells differ. Second, blood cells in one study (1) were incubated with endotoxin in phosphate-buffered saline without serum or Ca2+. The activation of leucocytes and the induction of pyrogen production may differ under these circumstances. In preliminary studies (not reported), pre-incubation of leucocytes with salicylate in a serum-buffer medium appeared to augment rather than inhibit the action of endotoxin on leucocyte pyrogen release. A similar, but smaller, effect occurred when salicylate was added after the endotoxin (see Table 2 ). Salicylate may increase the availability of endotoxin for leucocyte activation by interfering with binding sites for endotoxin on plasma proteins (17 in a serum-buffer medium and exposed to salicylate both before and after activation by two inflammatory agents. The lack of effect of the drug under these conditions, then, seems significant. In addition to the unimpaired capacity for pyrogen release shown in these studies, salicylate-treated leucocytes exhibit normal phagocytosis and release of lysosomal enzymes (19) . The stability of isolated human leucocyte lysosomes is reportedly not enhanced by salicylate (19) , in contrast to rat liver lysosomes (20) .
Data on anti-inflammatory effects of salicylates do not include evidence for altered leucocyte function (21 ) .
Recently, it has been proposed that salicylate may act as an antipyretic by inhibiting the synthesis and release of certain pyrogenic prostaglandins at sites of inflammation or in the brain (2, 3) . Release of pyrogenic prostaglandins from rabbit exudate leucocytes in vitro after phagocytosis has been reported (22) , although the effect of salicylate on this process was not examined. Our studies did not detect any reduction in the release of pyrogenic substances from salicylate-treated leucocytes. Thus, they do not support the hypothesis that salicylate suppresses fever by inhibiting prostaglandin release from leucocytes at peripheral sites of inflammation.
Our experiments confirmed the findings of some investigators (5, 10), but not another (1) , that after administration of parenteral salicylate, rabbits have less febrile response to injection of preformed endogenous pyrogen. This salicylate effect, although definite, is small, and its demonstration may require careful attention to accurate assay techniques. Also, when salicylate is given after the onset of experimental (6) or clinical fever, rather than before, as in this model, its antipyretic effect is pronounced.
Our findings, then, do not support the theory that the antipyretic action of salicylate results from peripheral effects on release of pyrogen from blood leucocytes. They do provide support for the concept that the action of salicylate on fever is primarily a central one.
Note added in proof: Other work indicating lack of effect of salicylate on progen release from cells of other species has recently been published (23) (24) (25) .
